FindTrial
Sign In

Survival benefit of adjuvant chemotherapy in patients with high-risk upper tract urothelial carcinoma administered radical nephroureterectomy

Survival benefit of adjuvant chemotherapy in patients with high-risk upper tract urothelial carcinoma administered radical nephroureterectomy

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1900027924
Enrollment
Unknown
Registered
2019-12-04
Start date
2020-01-01
Completion date
Unknown
Last updated
2019-12-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

high-risk upper tract urothelial carcinoma

Interventions

1:laparoscopic RNU treatmen
2:laparoscopic RNU+ACT

Sponsors

Beijing Anzhen Hospital, Capital Medical University
Lead Sponsor

Eligibility

Sex/Gender
Male

Inclusion criteria

Inclusion criteria: The patient meeting anyone factor of inclusion criteria was diagnosed as high-risk UTUC: hydronephrosis, tumor size over 1 cm high-grade cytology, multifocal disease, and previous radical cystectomy for bladder cancer or variant histology.

Exclusion criteria

Exclusion criteria: Previous neoadjuvant chemotherapy, previous Cisplatin-based chemotherapy for bladder cancer, ECOG >=3, preoperative eGFR<60 mL/min, postperative eGFR<60 mL/min (one month after surgery), dysfunction of the contralateral kidney, metastasis, other malignant tumors or severe cardiopulmonary disease, and interruption of follow-up.

Design outcomes

Primary

MeasureTime frame
PFS (time to radiographic progression);—

Secondary

MeasureTime frame
OS (time to death regardless of cause);CSS (time elapsed from RNU to cancer death);—

Countries

China

Contacts

Public ContactYong Luo

Beijing Anzhen Hospital, Capital Medical University

luoyonganzhen@163.com+86 15910712696

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026